The role of adiponectin gene variants in glycemic control in patients with Type 2 diabetes

Endocr Res. 2014;39(1):13-7. doi: 10.3109/07435800.2013.794427. Epub 2013 Jun 17.

Abstract

The aim of this study was to investigate the association between glycemic control in Type 2 diabetes mellitus patients and common genetic variants of ADIPQO gene. A total of 427 Type 2 diabetes patients were recruited in the study and divided into two groups: 172 patients with good glycemic control and 249 with poor glycemic control. Genotyping of C11377G, G276T and T45G ADIPQO SNPs were carried out using restriction fragment length polymorphisms-polymerase chain reaction. The results showed that C11377G ADIPQO SNP is strongly associated with glycemic control in Type 2 diabetes patients. Patients with the GG genotype at adiponectin C11377G had better glycemic control than those with CC or CG genotypes. However, other examined SNPs were not correlated with glycemic control in Type 2 diabetes patients. Other parameters that impacted glycemic control include duration of the disease (p < 0.01), use of insulin therapy (p < 0.01) and presence of neuropathy complications (p < 0.01). However, no contribution was observed for gender, statin use, lipid profile and other oral medications to glycemic control (p > 0.05). Glycemic control among Type 2 diabetes patients might be affected by variants in ADIPQO gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood
  • Adiponectin / genetics*
  • Adult
  • Aged
  • Blood Glucose / genetics
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Genotype*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Insulin Resistance / genetics*
  • Leptin / blood
  • Male
  • Middle Aged
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide
  • Treatment Outcome

Substances

  • Adiponectin
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Leptin